Dravet Syndrome clinical trials

Explore recruiting dravet syndrome clinical trials.

Recruiting dravet syndrome studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Dravet Syndrome trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults with Dravet Syndrome

Latvia, Spain, Portugal, Germany, France, Belgium +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Open-label, Single-arm, Phase 3 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to less Than 2 Years of Age with Dravet Syndrome

Germany, Belgium, Italy, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children and Adult Participants with Dravet Syndrome (ARGUS Trial)

Hungary, Poland, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase 1-2, Open-Label, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION337 in Patients with Dravet Syndrome

Spain, France, Belgium, Portugal, Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Bioavailability study of stiripentol after single oral administration of two different formulations (capsule and oral suspension) in 24 healthy subjects

France

Human Pharmacology (Phase I)- Other EU CTIS Study details

EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients with Dravet Syndrome

Spain, France, Italy, Poland, Sweden, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Dravet Syndrome trials by city

Dravet Syndrome in Toronto Dravet Syndrome in Vancouver Dravet Syndrome in Montreal Dravet Syndrome in Calgary Dravet Syndrome in Edmonton Dravet Syndrome in Ottawa Dravet Syndrome in Winnipeg Dravet Syndrome in Quebec City Dravet Syndrome in Hamilton Dravet Syndrome in Kitchener Dravet Syndrome in London Dravet Syndrome in Halifax Dravet Syndrome in New York Dravet Syndrome in Los Angeles Dravet Syndrome in Chicago Dravet Syndrome in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease